The detection and screening of mycotoxins by LC-MS/MS

Dr Stephen Lock PhD, Dr Ondrej Lacina PhD, Dr Florian Huebner
This webinar covers the different approaches to the detection of mycotoxin contamination in food by LC-MS/MS. Examples are covered using highly sensitive systems to simplify the extraction and analysis and detection of these toxins at low levels. The additional benefits of using accurate mass or SelexION™ ion mobility in this application area are also covered.

Presentations:

* Screening of mycotoxins in Food by triple quadrupole and qtrap LC-MS/MS - Dr Stephen Lock PhD

* High Resolution Tandem Mass Spectrometry in mycotoxin analysis: higher selectivity to improve analyte confirmation - Dr Ondrej Lacina PhD

* Boosting the performance of LC-MS/MS analysis of mycotoxins and their transformation products by using innovative separation techniques - Dr. Florian Huebner
Sep 20 2012
63 mins
The detection and screening of mycotoxins by LC-MS/MS
More from this community:

Medical Research

Webinars and videos

  • Live and recorded (318)
  • Upcoming (6)
  • Date
  • Rating
  • Views
  • This webinar focuses on new methods and applications in food contamination analysis, bringing together some of the leading experts in food contact materials (FCM) and provides an interactive learning environment for scientists working in this field.

    As food quality and food integrity has become a major topic for the consumer, the penetration path of contaminants in our food chain deriving from the food production and/or the food packaging and storage conditions is gaining attention. Fast and reliable ways of sample preparation and analysis are discussed showing up-to-date examples and how the regulations are applied.
    ______________
    ** Meet the speakers **

    - Sabrina Moret (Associate Professor, Dept. Food Science, University of Udine)

    - Duncan Goodwin (Director of Technical Services, NSF)

    - Susanne Feifel (Product Group Manager for Kjeldahl, Elemental Analysis and Extraction, BÜCHI)
    ______________
    ** What will you gain from this webinar? **

    - You will be provided with tangible ways to streamline your sample preparation to detect mineral oil hydrocarbons in cardboard and food as well as bisphenol A in canned food.

    - BUCHI´s solutions for these applications are presented using examples from industry.

    - Furthermore, you will learn about health and safety risks in the field of food packaging and storage. This will be linked to up-to-date information from the leading regulatory authorities.
  • Alongside established drug target classes, innovative approaches are addressing previously undruggable target classes such as protein–protein interactions. This webinar will provide an overview of how compound profiling using the PLA® (Proximity Ligation Assay) technology can be used for in situ analysis of protein interactions by high content screening as part of the Hit-to-Lead workflow, the key advantage being the ability to provide evidence for target engagement of the compound.

    Proximity ligation is a highly specific and sensitive technology to monitor individual proteins, their interactions and post-translational modifications in situ. It provides single molecule resolution and objective and unbiased quantification in cells and tissues on endogenous expression levels.

    Dr. Bernhard Ellinger (Principal Scientist, European ScreeningPort) will describe how the PLA technology has been optimised for use in an automated 384-well screening format with routines for automated image analysis including spot detection, localisation and quantification. He will present a case study of a small molecule drug discovery project performed in collaboration with a biotech partner. The target mechanism involved the disruption of the interaction between amyloid ß oligomers and RAGE (Receptor for Advanced Glycation Endproducts). Profiling of compounds during Hit-to-Lead stages has involved a variety of high content functional cellular assays including PLA. He will discuss the use of PLA in 384-well format as part of a Hit-to-Lead screening cascade to monitor compound-mediated disruption of this receptor-ligand complex.

    Thomas Juehne (Principal Scientist, Sigma-Aldrich) will discuss Duolink®, which is based on the in situ PLA technology, a highly sensitive and selective way of direct in cell visualisation of endogenously expressed proteins and their interacting partners enabling the use of unmodified primary cells.

    The following trademarks are owned by Olink AB: Duolink® and PLA®
  • SLC transporter-mediated drug–drug interactions (DDI) can significantly impact the pharmacokinetics and safety profiles of drugs. The regulatory agencies (FDA/EMA) recent guidance documents recommend testing six SLC transporters for potential DDI: OATP1B1, OATP1B3, OAT1, OAT3, OCT1 and OCT2. The 2013 drug transporter white paper published by the International Transporter Consortium (ITC) identified additional drug transporters relevant to drug development, including the Multidrug and Toxin Extrusion SLC transporters: MATE1 and MATE2-K. The webinar will introduce a novel cell-based SLC transporter model system - the recently launched “Corning™ TransportoCells™” - for studying regulatory agency recommended SLC transporters. The new system provides a convenient “thaw and go”, high performing mammalian cell model which supports regulatory agency recommendations for evaluating transporter mediated drug-drug interactions in vitro. In this webinar, we will provide an overview of the product validation and applications for the TransportoCells™ transporter model system. Validation data will also be presented for the newly available MATE1 and MATE2-K Corning™ TransportoCells™.
  • Despite our dependence on cultured cells as models, issues surrounding cell identity, choice of appropriate cell lines, conditions of their growth and storage, microbial contamination and over-passaging are often overlooked or misunderstood. Mistakes can have devastating impacts on the legitimacy and reproducibility of science but potentially also, on careers, reputations and funding streams.

    Topics covered:

    Solutions and options for managing cell culture processes
    The Impact of misidentification
    The international consensus on cell identity and qualification
  • Attend this webinar to discover:

    •Changes to healthcare delivery: hospitals of the future, aging in place, cost of care innovations
    •Role of the patient and consumer influence
    •Role of emerging regions as a consumer and competitor
    •Novel industry business models
    •Key disruptive technologies
  • The truth about delivering clinical research in the UK

    • Are you looking to deliver your research in Europe?
    • Need multiple, reliable sites in each country?
    • Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that’s all changed. Over the last five years the research landscape here has changed dramatically allowing us to make great strides in delivering research for the life-sciences industry. So whether you’re a small CRO, a medium med tech, or a pharma giant - we can help you.

    The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research.. This session will be hosted by Jonathan Sheffield, CEO of the NIHR Clinical Research Network. It will include performance data that will demonstrate why the UK should be your first choice for clinical research. You can find out:

    • How much the UK’s market volume of commercial contract research (supported by the NIHR) has changed
    • What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR)
    • On average how many days it takes for NHS sites to get regulatory approval for research to take place (with NIHR support)
    • What percentage of commercial contract studies (supported by the NIHR) are delivered to time and target
    • How the NIHR is keeping clinical research in the public eye
    • How the UK is sharpening its competitive edge by achieving more and more key first global patient milestones
  • The Health Service Journal Clinical Research Impact award winner, Sussex Partnership NHS Foundation Trust, has created an inclusive research network which has given the public, patients, carers and staff the opportunity to learn about and get involved with research in their community.

    Find out why Sussex Partnership were determined to make clinical research everyone’s business and how they implemented their new initiatives.

    This session shares best practice and is aimed at NHS Trusts/primary care practices.
  • Three-dimensional (3D) cell culture environments provide structural and biochemical cues for cellular differentiation and functionality. For specialized cell types such as primary cells, a two-dimensional growth substrate may not be sufficient to support complex cellular behaviors such as cell polarity, morphology, signal transduction, and tissue-specific gene expression. This webinar will highlight applications that rely on 3D materials and systems, including Corning ® Matrigel® Matrix (reconstituted basement membrane), Collagen Type I, Corning PuraMatrix™ Peptide Hydrogel, and permeable supports (cell culture inserts). To demonstrate the effectiveness of these environments, the biological and functional properties of a variety of cell types will be discussed.
  • Frost & Sullivan will provide an outlook for healthcare in 2014 with detailed insights on the regulatory challenges, investment trends, innovation temperature and emerging business models in the Asia-Pacific Healthcare market.
  • M22 - Neue Behandlungsansätze mit IPL und ResurFX-
    Dr. med. Gerd Kautz.
    PB-1005026Rev A
  • Channel
  • Channel profile
Up Down
  • Bio Contamination Risk Profiling and Proactive Response Jun 26 2014 2:00 pm UTC 60 mins
    This webinar will give an overview of the recently released UK Pharmaceutical and Healthcare Science Society (PHSS) Technical Monograph #20- Bio-contamination, characterization, control, monitoring and deviation management in controlled/ GMP classified areas. The concept of Risk Profiling and Proactive Response (RPPR) to bio-contamination in GMP classified areas, focusing on preventing contamination and not just monitoring for compliance will be presented. How trending environmental monitoring data holistically across all supporting areas can detect an increasing risk of a contamination event in Grade A zones will be examined. In particular, the value of using real-time airborne viable particle detection as part of holistic monitoring strategy for risk escalation will be discussed.

    Many organizations are pro-actively exploring Rapid Microbiological Methods (RMMs). Real-time airborne viable particle counting is an RMM that is generating great interest. The potential opportunities of improved product quality and efficiencies, whilst maintaining patient safety are too significant to ignore. Cases where this technology is providing value today in a pharmaceutical manufacturing environment will be presented. Included will be a brief discussion of critical performance characteristics of real-time viable particle detectors which should be considered when selecting an instrument to monitor GMP classified areas.
  • Food contamination an issue? – Discover solutions for your everyday preparation Recorded: Apr 10 2014 74 mins
    This webinar focuses on new methods and applications in food contamination analysis, bringing together some of the leading experts in food contact materials (FCM) and provides an interactive learning environment for scientists working in this field.

    As food quality and food integrity has become a major topic for the consumer, the penetration path of contaminants in our food chain deriving from the food production and/or the food packaging and storage conditions is gaining attention. Fast and reliable ways of sample preparation and analysis are discussed showing up-to-date examples and how the regulations are applied.
    ______________
    ** Meet the speakers **

    - Sabrina Moret (Associate Professor, Dept. Food Science, University of Udine)

    - Duncan Goodwin (Director of Technical Services, NSF)

    - Susanne Feifel (Product Group Manager for Kjeldahl, Elemental Analysis and Extraction, BÜCHI)
    ______________
    ** What will you gain from this webinar? **

    - You will be provided with tangible ways to streamline your sample preparation to detect mineral oil hydrocarbons in cardboard and food as well as bisphenol A in canned food.

    - BUCHI´s solutions for these applications are presented using examples from industry.

    - Furthermore, you will learn about health and safety risks in the field of food packaging and storage. This will be linked to up-to-date information from the leading regulatory authorities.
  • Detection, quantification and visualisation of protein interactions by HCS Recorded: Apr 8 2014 59 mins
    Alongside established drug target classes, innovative approaches are addressing previously undruggable target classes such as protein–protein interactions. This webinar will provide an overview of how compound profiling using the PLA® (Proximity Ligation Assay) technology can be used for in situ analysis of protein interactions by high content screening as part of the Hit-to-Lead workflow, the key advantage being the ability to provide evidence for target engagement of the compound.

    Proximity ligation is a highly specific and sensitive technology to monitor individual proteins, their interactions and post-translational modifications in situ. It provides single molecule resolution and objective and unbiased quantification in cells and tissues on endogenous expression levels.

    Dr. Bernhard Ellinger (Principal Scientist, European ScreeningPort) will describe how the PLA technology has been optimised for use in an automated 384-well screening format with routines for automated image analysis including spot detection, localisation and quantification. He will present a case study of a small molecule drug discovery project performed in collaboration with a biotech partner. The target mechanism involved the disruption of the interaction between amyloid ß oligomers and RAGE (Receptor for Advanced Glycation Endproducts). Profiling of compounds during Hit-to-Lead stages has involved a variety of high content functional cellular assays including PLA. He will discuss the use of PLA in 384-well format as part of a Hit-to-Lead screening cascade to monitor compound-mediated disruption of this receptor-ligand complex.

    Thomas Juehne (Principal Scientist, Sigma-Aldrich) will discuss Duolink®, which is based on the in situ PLA technology, a highly sensitive and selective way of direct in cell visualisation of endogenously expressed proteins and their interacting partners enabling the use of unmodified primary cells.

    The following trademarks are owned by Olink AB: Duolink® and PLA®
  • Pharmaceutical Manufacturing Regulations: Navigating the Complexities Recorded: Jan 30 2014 67 mins
    During this webinar learn more about unconventional approaches to enhance quality programs with the use of modern handheld technology...

    While regulatory enforcement agencies around the world have increased scrutiny on quality assurance/quality control programs, pharmaceutical manufacturers are increasingly looking for ways to lean out the manufacturing process without compromise to product quality. This push and pull conundrum has manufacturers seeking guidance on global industry regulations while searching for alternatives to legacy quality practices. With the expanding supply chain and the onset of globalization, it is now more important than ever to adjust quality programs to improve efficiency but remain keen on effectiveness for the continued promise of product quality and patient safety.

    Handheld Raman technology is currently being implemented by global pharmaceutical manufacturers and regulatory agencies around the world providing an effective alternative approach to increased testing and heightened quality programs.
  • Combining UPLC, QbD and Software-Guided Validation for Rapid Method Development Recorded: Dec 9 2013 64 mins
    Method development and validation are essential parts of the pharmaceutical drug approval process. As process modifications are made and approval criteria become increasingly stringent, changes to the validated method are sometimes necessary. A Quality by Design (QbD) approach to method development uses statistical design of experiments (DoE) to generate a robust method ‘design space’. The design space defines a region in which changes to method parameters will not significantly affect the results, incorporating risk-based assessment of the final method. Rather than developing and validating a single method and proceeding through re-validation as modifications are made, a design space incorporates allowable flexibility into the method.

    A QbD approach is demonstrated here in the development of a stability-indicating method, using UPLC for fast, sensitive separations, and software-driven validation. The flexibility of transferring methods between UPLC and HPLC will also be demonstrated. This streamlined approach to method development affords considerable cost savings as well as a significantly more robust and quality submission to regulatory authorities for faster drug approval.
  • Best Practices in Managing Microbial Excursions Recorded: Dec 3 2013 57 mins
    Learn from industry experts some practices to help better manage the investigation process and how to design processes to minimize unnecessary excursions.

    Microbial excursions as a result of an out of specification result from a quality control test can be time consuming and costly. The investigation of the root cause, analysis of the risk to the product, and determination of corrective/preventative actions take hours of manpower and resources and often are caused by issues around personnel practices, keying errors, and incubation errors.

    Attendees will learn:

    - What is an excursion?
    - How to identify risk in an excursion
    - Tools to help manage the process
  • RMMs for Environmental Monitoring, Validation & Viable Particle Detection Recorded: Nov 19 2013 60 mins
    There are critical performance characteristics of real-time viable particle detectors that should be considered when evaluating an instrument for your application. To help with these considerations the science behind a real-time viable particle counter and the information this technology can deliver in real-time will be presented. Applications where real-time airborne viable particle detection can provide value today in a pharmaceutical manufacturing environment will be examined. The webinar will go on to give an overview of different Rapid Microbiological Methods (RMMs) that can be used for environmental monitoring, their applicability and their pros and cons. An overview of the forthcoming revision of EP 5.1.6 Alternative Methods for Control of Microbiological Quality and the impact this will have on the validation requirements for RMMs will be presented.
  • Whatever it takes for protein analysis: Kjeldahl, Dumas, or NIR Recorded: Oct 17 2013 63 mins
    A webinar focusing on the three most widely used technologies: Incoming or Outgoing goods inspections, at-line production control and quality control for declaration purposes.

    Processed food, beverage, feed or forage pass different steps in their production cycle requiring different technologies for the determination of nitrogen or protein. Whether you need fast qualification of raw material, or precise protein declaration of processed goods; Kjeldahl, Dumas and NIR solutions can be the methods to help you. There are many factors which influence the determination of the best fitting method. Whereas Kjeldahl is a proven method for all kind of sample matrices, Dumas excels in unattended processing at high throughput, and NIR is matchless in terms of immediate and comprehensive multi-component analysis. 

    This webinar will address the challenges that you are faced with in determining nitrogen or protein, and will present a range of technologies deigned to assist you in your processes.
  • Real-time monitoring: NIR as a PAT tool Recorded: Oct 8 2013 61 mins
    The Process Analytical Technology (PAT) and Quality by Design (QbD) initiatives have been of interest for pharmaceutical manufacturing in the last years. Implementation of PAT/QbD approach involves monitoring and controlling critical process parameters that influence the critical quality attributes of the product. One of the prime processes in pharmaceutical solid dosage form is granulation and drying process. With the PAT and QbD initiatives, the FDA aims to increase efficiency of the pharmaceutical production by real-time process analysis and control. Near Infrared spectroscopy (NIRS) is well accepted as a potential PAT analyzer due to its rapid and nondestructive technique that additionally requires no sample preparation.

    Metrohm is well-established in determining the moisture content by Karl Fischer titration in every conceivable type of product. To provide advance solutions for pharmaceutical customers, Metrohm now is moving forward, bringing NIRS to help customers to optimize the use of raw materials and to consistently run production closer to target specifications with time- and cost-saving analytical techniques.

    During this webinar, we will be showing the use of NIR in the process that allows for monitoring low levels of residual moisture and other process constituents to yield better process control and endpoint determination. Additionally, we will be focusing on:
    •Developing robust and precise method
    •Minimizing implementation efforts
    •Ensuring calibration model transferability between analyzers.
  • Advantages of Handheld Raman in the Pharmaceutical Industry Recorded: Sep 24 2013 55 mins
    Benefits and applications of handheld Raman and how it can help to facilitate compliance with PIC/S..

    This webcast will discuss the benefits and applications of handheld Raman, including the reasons the industry is interested in the technology, data integrity, method development, how samples are scanned, and challenges that have been conquered. We’ll also discuss PIC/S and how it is unifying the regulatory perspective globally, currently including 41 member countries with applications of Japan and Korea under review. We’ll discuss how these regulations are moving towards 100% container testing globally and how handheld Raman technology can help to achieve it, as well as the importance of validation of instrumentation and methodologies.
  • Metabolite Identification in the Real World Recorded: Jul 11 2013 62 mins
    Three industry leads present strategies and tools for Metabolite Identification...
  • From a Paper-based Trial Master File to a Streamlined Electronic Document... Recorded: Jun 11 2013 61 mins
    Webinar on the transformation of a Paper-based Trial Master File to a Streamline Electronic Document Management Solution. At Sanofi, managing clinical drug trials was primarily a paper-based process. The logistics of managing this paper-based process for dozens of concurrent trials was daunting, expensive, and time consuming. The company wanted to optimize this manual process with a streamlined digital signature-compliant document management solution operating in a global, web-based collaborative framework. To do this, Sanofi implemented a clinical trial portal, which is based on Microsoft SharePoint portal and collaboration technologies.
  • Validating a Rapid Method for Pharmaceutical Applications Recorded: May 16 2013 59 mins
    Validation of rapid methods continues to be an obstacle to greater adoption of these technologies. Some of the benefits of rapid methods are well articulated across industry literature, including the ability to release products much faster as well as intervene faster in the event of contamination in any part of the manufacturing process. Regulatory approval and the challenge of actually validating the rapid method for many applications continue to be viewed as stumbling blocks.
  • Leveraging cutting-edge Rapid Microbiological Methods... Recorded: Mar 21 2013 54 mins
    Focused on Rapid Microbiological Methods (RMMs), this one hour webinar will deliver information and insight from both an end user and a supplier in order to share with you compelling reasons to consider the use of RMMs to gain a better understanding of your environment while improving your competitive advantage.

    A combination of knowledgeable suppliers, a competitive market, motivated end users, and encouragement from regulatory bodies has placed a number of companies at the forefront of the race to implement an instantaneous and continuous rapid microbiological method (RMM) in their pharmaceutical manufacturing environment.

    A number of rapid microbiological methods have emerged, and various degrees of testing have been performed by RMM system suppliers and their end users to determine how such systems may be beneficial to and implemented in an environment where traditional monitoring methods have been utilized for over 100 years.
  • Accelerating and Automated Rapid Microbial Testing Recorded: Nov 14 2012 64 mins
    Rapid microbial testing methods in quality control continue to gain acceptance in pharmaceutical manufacturing, but most companies continue to use manual, traditional methods. The ability to uncover results in less time than traditional methods provides compelling benefits to manufacturers. These benefits can be realized in environmental monitoring, sterility testing, water and bioburden testing.

    Learn from experts where rapid technologies, like the Growth Direct™ System can have an impact on microbial quality control and ultimately manufacturing.

    Attendees will learn:

    - The limitations of the traditional methods
    - The importance of non-destructive testing
    - The benefits of automated, rapid detection
  • Real-time Airborne Viable Particle Detection Recorded: Oct 18 2012 62 mins
    Technology overview and applicability to pharmaceutical quality systems.

    A new family or Rapid Micro Method (RMM), real time viable particle detection based on Laser Induced Fluorescence (LIF), has recently been introduced. Sometimes referred to as optical spectroscopy, these instruments provide the ability to continuously measure for the presence of viable particles in real time. An overview of LIF technology will be presented along with a detailed look at TSI’s implementation in the BioTrak® Real Time Viable Particle Detector highlighting critical instrument performance parameters.

    Several application scenarios will be reviewed in the context of current regulatory initiatives such as QbD, ICH Q8, Q9, Q10 and PAT. These applications can form a framework of increased knowledge resulting in a better understanding of the manufacturing process leading to improved product quality in addition to financial benefits.
  • Handheld Raman: Cut costs, improve efficiency & move toward 100% testing Recorded: Sep 27 2012 62 mins
    In this one hour instructional webinar, we discuss how handheld Raman is being used to streamline the pharmaceutical manufacturing process and reduce pharmaceutical product recalls and plant shutdowns. We provide a brief overview of typical incoming raw material inspection processes and discuss how handheld Raman increases productivity and satisfies stringent cGMP requirements. We also discuss how recent developments in handheld Raman technology will continue to enable wider and faster deployment to achieve the goal of 100% testing of raw materials. Lastly, we discuss the importance of a simplified user interface for non-technical users and how advances in technology have addressed this need.
  • The detection and screening of mycotoxins by LC-MS/MS Recorded: Sep 20 2012 63 mins
    This webinar covers the different approaches to the detection of mycotoxin contamination in food by LC-MS/MS. Examples are covered using highly sensitive systems to simplify the extraction and analysis and detection of these toxins at low levels. The additional benefits of using accurate mass or SelexION™ ion mobility in this application area are also covered.

    Presentations:

    * Screening of mycotoxins in Food by triple quadrupole and qtrap LC-MS/MS - Dr Stephen Lock PhD

    * High Resolution Tandem Mass Spectrometry in mycotoxin analysis: higher selectivity to improve analyte confirmation - Dr Ondrej Lacina PhD

    * Boosting the performance of LC-MS/MS analysis of mycotoxins and their transformation products by using innovative separation techniques - Dr. Florian Huebner
  • New monitoring methods improve compliance, reduce costs Recorded: Mar 20 2012 64 mins
    Watch presentations from experts in the fields of monitoring and compliance to pharmaceutical water and cleanroom facility standards:

    In this webinar you will learn:

    * How to stop using paper printouts for particle counting results while maintaining 21 CFR part 11 Compliance

    * How to meet EP TOC requirements with an on-line TOC analyzer designed for PAT and Real-Time-Release

    * What changes can we expect in ISO 14644 and 14698
Webinars for the pharmaceutical, food & beverage industries
Hear the leading industry experts talk about the important pharmaceutical, food & beverage manufacturing topics.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: The detection and screening of mycotoxins by LC-MS/MS
  • Live at: Sep 20 2012 8:30 am
  • Presented by: Dr Stephen Lock PhD, Dr Ondrej Lacina PhD, Dr Florian Huebner
  • From:
Your email has been sent.
or close
You must be logged in to email this